ProfileGDS5678 / 1424882_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 94% 93% 92% 94% 95% 96% 95% 94% 94% 95% 94% 94% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.3284895
GSM967853U87-EV human glioblastoma xenograft - Control 28.3085394
GSM967854U87-EV human glioblastoma xenograft - Control 38.009393
GSM967855U87-EV human glioblastoma xenograft - Control 47.74192
GSM967856U87-EV human glioblastoma xenograft - Control 58.2377394
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3386295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.6554596
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.3216995
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.1614794
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.039694
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.3963595
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.1116594
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.1408194
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.0600394